Metabolic Syndrome - About
Metabolic Syndrome is associated with sedentary lifestyle .It makes a person more prone to develop type 2 diabetes and coronary artery disease.
Source: medindia.net
Elevated Triglycerides News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Elevated Triglycerides. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Elevated Triglycerides Today - Breaking & Trending Today
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
-- Approval of VAZKEPA® to Reduce the Risk of Cardiovascular Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in... | April 4, 2023
Source: marketscreener.com
Investegate |Amarin Corporation plc Announcements | Amarin Corporation plc: Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
Investegate announcements from Amarin Corporation plc, Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
Source: investegate.co.uk
Amarin Corporation plc: Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
-- Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT
Source: finanznachrichten.de
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021
Message : Required fields Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy Effect on coronary plaque stabilization reported to be significant at 9 months and sustained at 18 months DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that further analyses from the Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: EVAPORATE Trial were presented as Late-Breaking ...
Source: marketscreener.com